These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1377 related items for PubMed ID: 28635560

  • 1. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [Abstract] [Full Text] [Related]

  • 2. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M.
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA, Negrão MV, de Freitas RM, Papadia C, Lima JV, Fukushima JT, Simão EF, Kulcsar MA, Tavares MR, Jorge AA, de Castro G, Hoff PM, Hoff AO.
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC.
    Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
    [Abstract] [Full Text] [Related]

  • 5. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshida K, Sakata Y, Yoshida A.
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [Abstract] [Full Text] [Related]

  • 6. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS.
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [Abstract] [Full Text] [Related]

  • 7. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME, Habra MA.
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
    Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M.
    BMC Cancer; 2011 Aug 11; 11():349. PubMed ID: 21834960
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib in metastatic thyroid cancer: a systematic review.
    Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME.
    Oncologist; 2014 Mar 11; 19(3):251-8. PubMed ID: 24563075
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P.
    Expert Rev Anticancer Ther; 2015 Mar 11; 15(8):863-74. PubMed ID: 26152651
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
    Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, DECISION investigators.
    Lancet; 2014 Jul 26; 384(9940):319-28. PubMed ID: 24768112
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L, Huang W, Chen L, Ting J, Cao V.
    Thyroid; 2017 Aug 26; 27(8):1043-1052. PubMed ID: 28486081
    [Abstract] [Full Text] [Related]

  • 17. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul 26; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 18. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, Todo T, Rito K, Takahashi S.
    Endocr Pract; 2017 Feb 26; 23(2):149-156. PubMed ID: 27819766
    [Abstract] [Full Text] [Related]

  • 19. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
    Kim M, Jin M, Jeon MJ, Kim EY, Shin DY, Lim DJ, Kim BH, Kang HC, Kim WB, Shong YK, Kim HK, Kim WG.
    Thyroid; 2023 Jan 26; 33(1):91-99. PubMed ID: 35443825
    [Abstract] [Full Text] [Related]

  • 20. Sorafenib for the treatment of thyroid cancer: an updated review.
    Krajewska J, Handkiewicz-Junak D, Jarzab B.
    Expert Opin Pharmacother; 2015 Mar 26; 16(4):573-83. PubMed ID: 25605317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.